New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma

被引：0
|
作者：
Cécile Teuma
Marie Perier-Muzet
Solenne Pelletier
Mathilde Nouvier
Mona Amini-Adl
Frédérique Dijoud
Gérard Duru
Luc Thomas
Denis Fouque
Maurice Laville
Stéphane Dalle
机构：
[1] Centre Hospitalier Lyon Sud,Department of Nephrology
[2] Centre Hospitalier Lyon Sud,Department of Dermatology
[3] Université de Lyon,UCBL, INSERM
[4] Centre de Recherche en Cancérologie de Lyon,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Kidney failure; BRAF inhibitor; Vemurafenib; Metastatic melanoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：419 / 426
页数：7
相关论文
共 50 条
  • [1] New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma
    Teuma, Cecile
    Perier-Muzet, Marie
    Pelletier, Solenne
    Nouvier, Mathilde
    Amini-Adl, Mona
    Dijoud, Frederique
    Duru, Gerard
    Thomas, Luc
    Fouque, Denis
    Laville, Maurice
    Dalle, Stephane
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 419 - 426
  • [2] VEMURAFENIB (B-RAF INHIBITOR) ASSOCIATED UVEITIS IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA
    Sandhu, Sukhpal S.
    Ling, Cecilia
    Lim, Lyndell
    Zamir, Ehud
    Stawell, Richard J.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2012, 40 : 118 - 118
  • [3] VEMURAFENIB B-raf Kinase Inhibitor Oncolytic
    Puzanov, I.
    Flaherty, K. T.
    Sosman, J. A.
    Grippo, J. F.
    Su, F.
    Nolop, K.
    Lee, R. J.
    Bollag, G.
    DRUGS OF THE FUTURE, 2011, 36 (03) : 191 - 199
  • [4] B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
    Roos, Wynand P.
    Quiros, Steve
    Krumm, Andrea
    Merz, Stephanie
    Switzeny, Olivier Jerome
    Christmann, Markus
    Loquai, Carmen
    Kaina, Bernd
    ONCOTARGET, 2014, 5 (24) : 12607 - 12620
  • [5] VEMURAFENIB AS A SELECTIVE INHIBITOR OF THE SERINE/THREONINE-PROTEIN KINASE B-RAF, USED IN THE TREATMENT OF MELANOMA
    Kubica, Krzysztof
    Mazurek, Aleksander
    BIULETYN WYDZIALU FARMACEUTYCZNEGO WARSZAWSKIEGO UNIWERSYTETU MEDYCZNEGO, 2016, (08):
  • [6] Management of metastatic melanoma: B-raf kinase inhibitors
    McCormack, C.
    McArthur, G.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2010, 51 : A3 - A3
  • [7] Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusiasm?
    Dasanu, Constantin A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (01) : 205 - 206
  • [8] Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib
    Orlandi, Paola
    Banchi, Marta
    Vaglini, Francesca
    Carli, Marco
    Aringhieri, Stefano
    Bandini, Arianna
    Pardini, Carla
    Viaggi, Cristina
    Lai, Michele
    Ali, Greta
    Ottani, Alessandra
    Vandini, Eleonora
    Guidi, Patrizia
    Bernardeschi, Margherita
    La Rocca, Veronica
    Francia, Giulio
    Fontanini, Gabriella
    Pistello, Mauro
    Frenzilli, Giada
    Giuliani, Daniela
    Scarselli, Marco
    Bocci, Guido
    BIOCHEMICAL PHARMACOLOGY, 2024, 219
  • [9] A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma
    Babu, Arunkumar
    Laila, Shiny P.
    Fernandez, Annette
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2021, 21 (15) : 2066 - 2074
  • [10] The role of B-RAF in melanoma
    Vanessa C. Gray-Schopfer
    Silvy da Rocha Dias
    Richard Marais
    Cancer and Metastasis Reviews, 2005, 24 : 165 - 183
12345